Wins for Cabozantinib in Kidney Cancer Brain Mets, Aggressive Disease Subtype

By News Health
29 minutes Ago

(MedPage Today) — DENVER — A majority of patients with non-locally treated brain metastases from kidney cancer remained free of metastatic progression for at least 6 months when treated with cabozantinib (Cabometyx), a small prospective study…

Source link : https://www.medpagetoday.com/meetingcoverage/ikcs/118548

Author :

Publish date : 2025-11-15 22:44:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

'I didn't tell anyone about my medical cannabis prescription'

What Heart Risk Was Tied to Melatonin Use?

AMA President: Fight When Necessary, but Also Find 'Common Ground'

Ivermectin for Kidney Cancer: Patients Have Questions, Clinicians Have Concerns

Right Therapy for Afib and a Stent; Fish Oil During Hemodialysis

From Opt-Out to Opt-In: A Dangerous Shift for Abortion Training